GSK Annual Report 2002

More documents

Recommendations

Info

140 GlaxoSmithKline Notes to the financial statements 38 Principal Group companies continued Europe Location Subsidiary undertaking Segment Activity % Netherlands Zeist GlaxoSmithKline BV Ph m Zeist GlaxoSmithKline Consumer Healthcare BV CH m Norway Oslo GlaxoSmithKline AS Ph m Poland Poznan GlaxoSmithKline Pharmaceuticals SA Ph m p 97 Warsaw GlaxoSmithKline Consumer Healthcare sp zoo CH m Portugal Lisbon GlaxoSmithKline-Produtos Farmaceuticos Lda (formerly Instituto Luso-Farmaco Lda) Ph m Republic of Carrigaline SmithKline Beecham (Cork) Ltd (Footnote (i)) Ph p Ireland Carrigaline SmithKline Beecham (Manufacturing) Ltd (Footnote (i)) Ph p Spain Madrid Glaxo Wellcome, SA Ph r m p Madrid SmithKline Beecham SA Ph m Sweden Mölndal GlaxoSmithKline AB Ph m Switzerland Muenchenbuchsee GlaxoSmithKline Investments (Switzerland) GmbH Ph,CH h Muenchenbuchsee GlaxoSmithKline International (Switzerland) GmbH Ph,CH h Muenchenbuchsee Glaxo Wellcome International (Footnote (i),(v)) Ph,CH h Muenchenbuchsee GlaxoSmithKline AG (formerly Glaxo Wellcome AG) Ph m Zug Adechsa GmbH Ph e Turkey Istanbul GlaxoSmithKline Ilaclari Sanayi ve Ticaret AS (formerly Glaxo Wellcome ISAS) Ph m p USA USA Philadelphia SmithKline Beecham Corporation Ph,CH e h r d m p s Pittsburgh GlaxoSmithKline Consumer Healthcare LP CH m p 66 Jersey City Block Drug Company, Inc CH h m p Wilmington GlaxoSmithKline Financial Inc Ph,CH f Wilmington SmithKline Beecham Holdings Corporation Ph,CH h Wilmington GlaxoSmithKline Holdings (Americas) Inc Ph,CH h Americas Bermuda Hamilton GlaxoSmithKline Insurance Ltd Ph,CH i Canada Mississauga GlaxoSmithKline Inc Ph,CH m p r Asia Pacific Australia Boronia Glaxo Wellcome Australia Ltd Ph m p Dandenong SmithKline Beecham (Australia) Pty Ltd Ph,CH m China Hong Kong GlaxoSmithKline Limited (formerly Glaxo Wellcome China Ltd) Ph m Tianjin Sino-American Tianjin Smith Kline & French Laboratories Ltd Ph m 55 India Mumbai GlaxoSmithKline Pharmaceuticals Ltd (Footnote (ii)) Ph m p 49 Nabha GlaxoSmithKline Consumer Healthcare Ltd (formerly SmithKline Beecham Consumer Healthcare Ltd) (Footnote (ii)) CH m p 40 Malaysia Selangor Darul Ehsan GlaxoSmithKline Pharmaceutical Sdn Bhd Ph m New Zealand Auckland GlaxoSmithKline NZ Limited Ph, CH m Pakistan Karachi Glaxo Wellcome Pakistan Ltd Ph, CH m p 79 Philippines Manila Glaxo Wellcome Philippines Inc Ph m Singapore Singapore Glaxo Wellcome Manufacturing Pte Ltd Ph p Singapore GlaxoSmithKline Pte Ltd (formerly Glaxo Wellcome Asia Pacific Pte Ltd) Ph m South Korea Seoul GlaxoSmithKline Korea Ph m p Taiwan Taipei Glaxo Wellcome Taiwan Ltd Ph m p
38 Principal Group companies continued Notes to the financial statements GlaxoSmithKline 141 Japan Location Subsidiary undertaking Segment Activity % Japan Tokyo GlaxoSmithKline KK Ph m p r 85 Kobe Block Drug Company (Japan) Inc CH m Latin America Argentina Buenos Aires GlaxoSmithKline Argentina SA Ph,CH m p Brazil Rio de Janeiro GlaxoSmithKline Brasil Lda (formerly SmithKline Beecham Brasil Lda) Ph,CH m p Colombia Bogota GlaxoSmithKline Colombia SA Ph,CH m Mexico Mexico City GlaxoSmithKline Mexico, SA de CV (formerly Glaxo Wellcome Mexico, SA de CV) Ph,CH m p Puerto Rico San Juan GlaxoSmithKline Puerto Rico Inc Ph m Hato Rey SB Pharmco Puerto Rico Inc Ph p Venezuela Caracas GlaxoSmithKline Venezuela CA (formerly Glaxo Wellcome CA) Ph m p Middle East Africa Egypt Cairo Glaxo Wellcome Egypt SAE Ph m p 90 South Africa Midrand GlaxoSmithKline South Africa (Pty) Ph m p (formerly Glaxo Wellcome South Africa (Pty) Ltd) Johannesburg SmithKline Beecham Consumer Healthcare (Pty) Ltd CH m p USA Location Associated undertaking % USA Teterboro, Quest Diagnostics, Inc. (Footnote (iii)) 23 New Jersey Footnotes (i) Exempt from the provisions of Section 7 of the Companies (Amendment) Act 1986 (Ireland) (ii) Consolidated as a subsidiary undertaking in accordance with Section 258 (4)(a) of the Companies Act on the grounds of significant influence (iii) This holding was reduced to 21 per cent in February 2003, following Quest’s acquisition of Unilab Corporation (iv) Incorporated in the Netherlands (v) Incorporated in the Republic of Ireland. + directly held wholly owned subsidiary of GlaxoSmithKline plc. Business segment: Ph Pharmaceuticals, CH Consumer Healthcare Business activity: d development, e exporting, f finance, h holding company, i insurance, m marketing, p production, r research, s service Full details of all Group subsidiary and associated undertakings will be attached to the company’s <strong>Annual</strong> Return to be filed with the Registrar of Companies.
Page 1 and 2:
Do more, feel better, live longer T
Page 3 and 4:
The Annual Report was approved by t
Page 5 and 6:
Joint statement by the Chairman and
Page 7 and 8:
04 GlaxoSmithKline Joint statement
Page 9 and 10:
Products - Pharmaceuticals Descript
Page 11 and 12:
Additionally, GlaxoSmithKline marke
Page 13 and 14:
Competition - Consumer Healthcare T
Page 15 and 16:
Operating activities Marketing and
Page 17 and 18:
Description of business GlaxoSmithK
Page 19 and 20:
Description of business GlaxoSmithK
Page 21 and 22:
Product approvals Country/Region Pr
Page 23 and 24:
As part of GlaxoSmithKline’s majo
Page 25 and 26:
Operating resources Intellectual pr
Page 27 and 28:
Compensation philosophy and program
Page 29 and 30:
Access to healthcare in the develop
Page 31 and 32:
GlaxoSmithKline gave unrestricted g
Page 33 and 34:
Corporate governance This section d
Page 35 and 36:
Corporate Executive Team (CET) JP G
Page 37 and 38:
The Annual General Meeting takes pl
Page 39 and 40:
Research and development Safety of
Page 41 and 42:
Remuneration report GlaxoSmithKline
Page 43 and 44:
The majority of the competitor pane
Page 45 and 46:
Performance graph 100 90 80 70 60 N
Page 47 and 48:
Non-Executive Directors Non-Executi
Page 49 and 50:
Non-Executive Directors’ share ar
Page 51 and 52:
Incentive plans Remuneration report
Page 53 and 54:
Operating and financial review and
Page 55 and 56:
2002 Year World economy The world
Page 57 and 58:
Pharmaceutical sales by therapeutic
Page 59 and 60:
Consumer Healthcare sales 2002 2001
Page 61 and 62:
Earnings 2001 2002 (restated) CER%
Page 63 and 64:
Contractual obligations and commitm
Page 65 and 66:
Funding, maturity and counterparty
Page 67 and 68:
Stricter regulatory controls also h
Page 69 and 70:
Operating and financial review and
Page 71 and 72:
Latin America reported eight per ce
Page 73 and 74:
Selected financial data UK/US GAAP
Page 75 and 76:
Financial statements GlaxoSmithKlin
Page 77 and 78:
Independent Auditors’ report to t
Page 79 and 80:
Consolidated statement of profit an
Page 81 and 82:
Consolidated statement of cash flow
Page 83 and 84:
Company balance sheet at 31st Decem
Page 85 and 86:
2 Accounting policies Consolidation
Page 87 and 88:
2 Accounting policies continued Sto
Page 89 and 90:
6 Segment information continued Not
Page 91 and 92: 7 Merger items, restructuring costs
Page 93 and 94: Notes to the financial statements G
Page 95 and 96: 13 Earnings per share Notes to the
Page 99 and 100: 19 Equity investments Notes to the
Page 105 and 106: 30 Legal proceedings The Group is i
Page 107 and 108: 30 Legal proceedings continued In F
Page 109 and 110: 30 Legal proceedings continued In 2
Page 111 and 112: 31 Acquisitions and disposals conti
Page 113 and 114: 32 Financial instruments and relate
Page 115 and 116: 32 Financial instruments and relate
Page 117 and 118: 33 Employee costs continued Notes t
Page 119 and 120: 33 Employee costs continued Notes t
Page 121 and 122: 34 Employee share schemes continued
Page 123 and 124: 34 Employee share schemes continued
Page 125 and 126: 37 Reconciliation to US accounting
Page 141: 38 Principal Group companies Notes
Page 145 and 146: Financial record GlaxoSmithKline 14
Page 153 and 154: Investor information GlaxoSmithKlin
Page 155 and 156: Shareholder information Ordinary sh
Page 157 and 158: Share capital GlaxoSmithKline 155 A
Page 159 and 160: Cross reference to Form 20-F GlaxoS
Page 161 and 162: Index A Access to healthcare 27 Acc
Page 163: Contact details INTERNET Informatio
show all

GSK Annual Report 2002

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?